Office
Journal Online
期刊信息
  • 临床肿瘤学杂志
    主管：解放军无锡联勤保障中心
    主办：解放军东部战区总医院
    编辑出版：临床肿瘤学杂志编辑部
    主编：秦叔逵
    编辑部主任：龚新雷
    地址：南京市杨公井34标34号
    邮编：210002
    电话：（025）84400143；80864363
    E-mail: lczlx@vip.163.com
    邮发代号：28-267
    刊期：月刊
    定价：每期15元，全年180元
    标准刊号： ISSN 1009-0460
    CN 32-1577/R
    　
Most Down Articles
Published in last 1 year | In last 2 years| In last 3 years| All| Most Downloaded in Recent Month | Most Downloaded in Recent Year|
In last 2 years
Please wait a minute...
Prevalence and prevention strategies of cervical cancer in the world and China
CAI Huilong, YUAN Weiguang, SUN Huixin.
Chinese Clinical Oncology    2023, 28 (01): 90-93.  
Abstract （456）      PDF（pc） （869KB）（830）       Save
 The International Agency for Research on Cancer (IARC) estimates 36 cancer incidence rate and mortality rates in 185 countries/regions through GLOBOCAN 2020 database. Globocan2020 database shows that cervical cancer is the fourth largest tumor in women in the world, whether it is morbidity or mortality. The harm of cervical cancer to women's health and its prevention and treatment are important public health issues facing the world. This paper will summarize and compare the incidence and death prevalence of cervical cancer in the world and China from the aspects of population characteristics, regional distribution and time change trend, and combined with the reported human papillomavirus and other risk factors, primary prevention and secondary prevention strategies of cervical cancer, in order to provide scientific clues for the prevention and treatment strategies of cervical cancer in the future.
Related Articles | Metrics
 Current status and prospect of immune checkpoint inhibitors in treatment of advanced soft tissue sarcoma
XUE Luxin, ZHANG Zhifan, LIU Fangcen, WANG Xiaolu, WANG Qin, LIU Baorui, LI Rutian.
Chinese Clinical Oncology    2023, 28 (01): 77-83.  
Abstract （256）      PDF（pc） （947KB）（791）       Save
 Soft tissue sarcomas (STS) are a rare group of mesenchymal malignancies except bone or cartilage, with a low incidence rate. Patients with advanced STS have limited treatment options, poor prognosis and high mortality. Recently, immune checkpoint inhibitors (ICIs) have made great breakthroughs in the field of tumor therapy, greatly improving the prognosis of patients with various malignancies. However, efficacy of ICIs in the treatment of STS remains unravelled. This review summarizes the role of the ICIs in various sets of advanced STS treatment and provides future research directions, hoping to serve as a reference for clinicians.
Related Articles | Metrics
Chinese Clinical Oncology    2023, 28 (01): 94-96.